Who
Richard Nolan Townsend
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Lexeo Therapeutics.
In numbers
- Trades disclosed
- 64
- Buys
- 0
- Sells
- 20
- Bought
- $0
- Sold
- $2.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Jan 2024
- Last trade
- 24 Sep 2026
- Last filed
- 28 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 28 Sep 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,500 at $0.00 | filing |
| 24 Sep 2026filed 28 Sep 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,500 at $0.00 | filing |
| 14 Sep 2026filed 28 Sep 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | $6,0972,306 at $2.64 | filing |
| 14 Sep 2026filed 28 Sep 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | $6,0882,306 at $2.64 | filing |
| 18 Aug 2026filed 19 Aug 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K3,345 at $4.95 | filing |
| 18 Aug 2026filed 19 Aug 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K3,345 at $4.95 | filing |
| 1 Jul 2026filed 1 Jul 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $116K25,947 at $4.48 | filing |
| 1 Jul 2026filed 1 Jul 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $116K25,947 at $4.48 | filing |
| 29 Jun 2026filed 1 Jul 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K3,342 at $5.06 | filing |
| 18 May 2026filed 20 May 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K3,342 at $5.06 | filing |
| 6 Apr 2026filed 7 Apr 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $313K55,000 at $5.69 | filing |
| 6 Apr 2026filed 7 Apr 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $313K55,000 at $5.69 | filing |
| 13 Mar 2026filed 17 Mar 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | $6,9352,623 at $2.64 | filing |
| 13 Mar 2026filed 17 Mar 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | $6,9252,623 at $2.64 | filing |
| 18 Feb 2026filed 20 Feb 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $65K10,173 at $6.38 | filing |
| 18 Feb 2026filed 20 Feb 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $65K10,173 at $6.38 | filing |
| 4 Feb 2026filed 6 Feb 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | —161,665 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —646,665 at $0.00 | filing |
News
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACMLXEO · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Richard Nolan Townsend; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.